DOCSLIB.ORG

Avastin + Letrozole

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Avastin + Letrozole Roche Q1 2015 sales Basel, 22 April 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. 3 Group Severin Schwan Chief Executive Officer 4 Q1 2015: Highlights Growth • Group sales +5%1 driven by HER2 franchise (+23%1), Avastin (+6%1), Actemra (+27%1) and Professional Diagnostics (+6%1) • Esbriet: Off to a strong start Innovation • Second Breakthrough Therapy Designation for anti-PDL1 • Phase 3 starts: Seven in immuno-oncology, etrolizumab in Crohn’s disease and taselisib in HR+ breast cancer M&A • Foundation Medicine: Transaction closed 1 CER=Constant Exchange Rates 5 Q1 2015: Strong sales growth 2015 2014 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 9.3 9.0 3 4 Diagnostics Division 2.5 2.5 2 6 Roche Group 11.8 11.5 3 5 CER=Constant Exchange Rates 6 Q1 2015: Continued strong growth in all regions CHFbn 6 +6% 5 +3% 4 +1% +10% 3 Diagnostics +3% +14% +6% Pharma 2 -3% * +1% 1 -10% +9% -2% 0 Japan International Europe US * Japanese sales impacted by consumption tax base effect CER=Constant Exchange Rates 7 Q1 2015: Sales growth for 5th consecutive year 10% 8% 8% 7% 6% 6% 6% 6% 6% 5% 5% 4% 5% 4% 4% 4% 4% 2% 2% 0% 0% 1% 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 11 11 11 11 12 12 12 12 13 13 13 13 14 14 14 14 15 All growth rates at Constant Exchange Rates (CER) 8 Progressing in Personalised Healthcare 60% of phase 2 & 3 products have PHC component Phase 2 Phase 3/Registration Marketed FIXa/FX bispecific MAb MAO-B inh PD-L1 MAb Tarceva® SERD GABRA5 NAM venetoclax (Bcl-2 inh) Zelboraf® CSF-1R MAb bitopertin alectinib (ALK inh) Erivedge® Ang2-VEGF MAb basimglurant taselisib Rituxan® ipatasertib V1 receptor antag cobimetinib Gazyva® polatuzumab vedotin crenezumab lebrikizumab Herceptin® lifastuzumab vedotin olesoxime etrolizumab Perjeta® gantenerumab glypican-3 MAb danoprevir Kadcyla® Flu A MAb ocrelizumab Avastin® LptD antibiotic lampalizumab Xeloda® Esbriet® Pulmozyme® Oncology Molecular Diagnostics Xolair® Immunology Tissue Diagnostics Infectious Diseases Actemra® Professional Diagnostics Neuroscience Lucentis® Ophthalmology 9 Roche: Making progress in advancing patient care Recognising innovation 2012-15 Breakthrough Therapy 6 Designations Rank Company # Q1 2015 Anti-PDL1 (NSCLC) 1 Roche 6 Esbriet 1 GSK 6 2014 Lucentis Diabetic Retinopathy 3 Novartis 5 Anti-PDL1 (bladder) 4 Merck 4 Alectinib 2013 5 JNJ 4 Gazyva Source: FDA 10 2015 outlook Group sales growth1 Low to mid-single digit Core EPS growth1 Ahead of sales growth2 Dividend outlook Further increase dividend in Swiss francs 1 At constant exchange rates 11 2 Excluding sale of filgrastim rights in 2014 Pharmaceuticals Division Daniel O’Day COO Roche Pharmaceuticals 12 Q1 2015 sales Innovation Outlook 13 Q1 2015: Strong sales growth driven by US and International 2015 2014 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 9,322 9,040 3 4 United States 4,392 3,873 13 6 Europe 2,178 2,425 -10 1 Japan 763 845 -10 -2 International 1,989 1,897 5 9 CER=Constant Exchange Rates 14 Q1 2015: Strong performance from oncology and immunology franchises; Esbriet off to a good start Herceptin +12% Perjeta +82% Esbriet n.a. MabThera/Rituxan +5% Avastin +6% Kadcyla +80% Actemra/RoActemra +27% Xolair +28% Lucentis -9% US Valcyte/Cymevene -41% Europe Pegasys -39% Japan International Xeloda -53% -200 -150 -100 -50 0 50 100 150 200 CHFm Absolute amounts and growth rates at Constant Exchange Rates (CER) 15 Q1 2015: Oncology products with +6% growth YoY CER growth Perjeta • Strong uptake of Perjeta & Kadcyla HER2 Herceptin +23% +23% • Accelerated growth of Herceptin Kadcyla • US: Continued uptake in ovarian, cervical and lung Avastin +6%+6% • EU: Growth in ovarian and breast MabThera/ Rituxan +4% • Increased usage across a variety of indications Tarceva --3%3% • In-class competition Xeloda --53%53% • Loss of exclusivity • Competitive pressure in US & EU Zelboraf --25%25% • Approval of coBRIM expected in 2015 CHFbn 0 1 2 CER=Constant Exchange Rates; Q1 2015 Oncology sales: CHF 5.8bn 16 HER2 franchise: Growth of Perjeta also driving Herceptin sales CHFm YoY CER growth 2'400 23% 23% 19% 23% 17% 20% 1'800 15% 7% 15% 1'200 600 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 13 13 13 13 14 14 14 14 15 Kadcyla Perjeta Herceptin CER=Constant Exchange Rates 17 Herceptin SC launched in 44 countries Conversion rate already exceeds 30% Number of countries where SC share of Herceptin sales in Herceptin SC has been launched launched countries 50 35% 30% 40 25% 30 20% 20 15% 10% 10 Sales market (%) Sales market share 5% Total number of countries of countries number Total 0 0% Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 13 13 13 14 14 14 14 15 13 13 13 14 14 14 14 15 18 Avastin: Strong growth across various indications and in all regions CHFm YoY CER growth 1'800 +9% +6% +11% Avastin Q1 2015 1'500 +1% • Main growth drivers are ovarian 1'200 (US; EU), lung (US) and cervical cancer (US) 900 • EU: Positive momentum in breast 600 cancer due to IMELDA • International (+11%) in all regions 300 Outlook 0 • EU launch in cervical cancer Q1 12 Q1 13 Q1 14 Q1 15 US Europe International Japan CER=Constant Exchange Rates 19 Immunology franchise remains driven by Actemra, Xolair and MabThera/Rituxan CHFm YoY CER growth 1'500 +20% • Actemra (+27%): SC launch and +11% +11% 1L monotherapy setting +5% 1'000 • Xolair (+28%): Allergic asthma and strong growth in Chronic Idiopathic Urticaria (CIU) post 500 FDA approval in Q1 ‘14 • MabThera/Rituxan (+11%): 0 Continues to grow in rheumatoid Q1 12 Q1 13 Q1 14 Q1 15 arthritis and vasculitis (GPA and Other (incl Esbriet) Pulmozyme MPA) CellCept Xolair Actemra SC Actemra IV MabThera/Rituxan GPA=Granulomatosis with polyangiitis; MPA=Microscopic polyangiitis 20 CER=Constant Exchange Rates Ophthalmology franchise: Competitive pressure on Lucentis; Fast Track status for lampalizumab USDm Lucentis sales Lucentis Q1 2015 500 • Continued competitive pressure in wAMD • First-in-class FDA approval to treat diabetic retinopathy (DR) in patients 400 with DME AMD Less-frequent than Lucentis outlook monthly dosing • Ongoing competition in AMD & DME 300 Lucentis • First sales in DR DME Lampalizumab update • FDA granted Fast Track status for 200 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 geographic atrophy (GA) 12 12 12 12 13 13 13 13 14 14 14 14 15 • Ph3 global enrollment well on track wAMD=wet age-related macular degeneration; DME=diabetic macular edema 21 Esbriet: Off to a strong start Esbriet sales (CHFm) 88 US launch off to strong start • Patients still in transition to full reimbursement post approval 44 • Establishing market leadership in IPF 36 32 27 European sales with continued growth • Label was strengthened by including ASCEND and pooled 1Y mortality data Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 22 Q1 2015 sales Innovation Outlook 23 Gazyva: First positive readout in iNHL CLL11: Ph III front-line chronic lymphocytic leukemia (CLL) Gazyva 1000mg IV + chlorambucil Front-line CLL MabThera/Rituxan + Primary end-point: PFS n=781 chlorambucil Approved in Q4 2013 chlorambucil GADOLIN: Ph III MabThera/Rituxan refractory indolent non-Hodgkin`s lymphoma (iNHL) Induction Maintenance CR, PR, Gazyva SD Gazyva + bendamustine q2mo x 2 years MabThera-refractory iNHL x 6 cycles Primary end-point: PFS n=411 Data at ASCO 2015 bendamustine x 6 cycles GOYA: Ph III diffuse large B-cell lymphoma (DLBCL) Gazyva x 8 cycles + Front-line DLBCL CHOP x 6 or 8 Primary end-point: PFS (aggressive NHL) n=1,418 MabThera x 8 cycles + CHOP x Trial to continue until 2016 6 or 8 GALLIUM: Ph III front-line indolent non-Hodgkin`s lymphoma (iNHL) Induction Maintenance Gazyva x 8 cycles + CHOP x 6 or Gazyva Gazyva x 8 cycles + CVP x 8 or q2mo x 2 years Front-line iNHL Gazyva x 6 cycles + benda. x 6 Primary end-point: PFS n=1,401 CR, PR Enrolment complete Q1 2014 MabThera x 8 cycles + CHOP x 6 or MabThera x 8 MabThera Data expected 2017 cycles + CVP x 8 or MabThera x 6 cycles + benda.
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Interferon-Based and Interferon-Free New Treatment Options
    Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt am Main Mode of action of Interferons natural immunomodulatory effects IFN-stimulated gene activation Antiviral Apoptotic Immunomodulatory activity activity activity B-cell proliferation Reduced transcription Elevates apoptosis by CTL proliferation Reduced translation multiple mechanisms MHC upregulation Reduced RNA stability Augments NK activity Host-mediated effects are important for DAA combination therapy • Potency and additive effects • Prevention of resistance and viral breakthrough Different types of Interferons Type I Interferons Type III Interferons Broad receptor Receptors distribution distributed throughout various primarily in body tissues epithelial cells and hepatocytes Antiviral effects Antiviral effects Adverse events of Type I IFNs treatment Peg‐Intron • Flu-like symptoms PegIFN‐2a Type III IFNs Potentially fewer • Haematologic IFN omega Peg‐IFN‐ adverse events disorders IFN‐alfa‐2b XL lambda than with type I • Psychiatric Belerofon (Peg‐rIL‐29) interferons symptoms Albuferon Locteron Adapted from 1. Marcello T et al. Gastroenterology 2006;131:1887–98; 2. Muir AJ et al. 2009 AASLD. Abstract 1591; 3. O'Brien TR. Nat Genet. 2009;41:1048–50. PEG-Interferon alfa / Ribavirin Approval studies: efficacy Approval study (n=1530) Approval study (n=1121) Therapy: IFN vs. PEG-IFN alfa 2b Therapy: IFN vs. PEG-IFN alfa 2a 1,0/1,5µg/kgKG
    [Show full text]
  • Version Introducing VHIO Foreword
    2017SCIENTIFIC REPORT Vall d'Hebron Institute of Oncology (VHIO) CELLEX CENTER C/Natzaret, 115 – 117 08035 Barcelona, Spain Tel. +34 93 254 34 50 www.vhio.net Direction: Amanda Wren Design: Parra estudio Photography: Katherin Wermke Vall d'Hebron Institute of Oncology (VHIO) | 2018 VHIO Scientific Report 2017 Index Scientific Report INTRODUCING VHIO CORE TECHNOLOGIES 02 Foreword 92 Cancer Genomics Group 08 2017: marking the next chapter of 94 Molecular Oncology Group VHIO's translational story 96 Proteomics Group 18 Scientific Productivity: research articles VHIO'S TRANSVERSAL CLINICAL 19 Selection of some of the most relevant TRIALS CORE SERVICES & UNITS articles by VHIO researchers published in 2017 100 Clinical Trials Office 25 A Golden Decade: reflecting on the 102 Research Unit for Molecular Therapy past 10 years of VHIO's translational of Cancer (UITM) – ”la Caixa” success story 104 Clinical Research Oncology Nurses 106 Clinical Research Oncology Pharmacy PRECLINICAL RESEARCH Unit 49 From the Director 50 Experimental Therapeutics Group RECENTLY INCORPORATED GROUPS 52 Growth Factors Group 110 Cellular Plasticity & Cancer Group 54 Mouse Models of Cancer Therapies 112 Experimental Hematology Group Group 114 Tumor Immunology 56 Tumor Biomarkers Group & Immunotherapy Group 116 Applied Genetics of Metastatic Cancer TRANSLATIONAL RESEARCH Group 61 From the Director 118 Chromatin Dynamics in Cancer Group 62 Gene Expression & Cancer Group 120 Prostate Cancer Translational Research Group 64 Stem Cells & Cancer Group 122 Radiomics Group CLINICAL
    [Show full text]
  • Roche/Genentech Managed RG7986 ADC R/R NHL CHU Chugai Managed IONIS IONIS Managed 74 Status As of January 28, 2016 PRO Proximagen Managed
    Roche 2015 results London, 28 January 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]
  • 2019 Icar Program & Abstracts Book
    Hosted by the International Society for Antiviral Research (ISAR) ND International Conference 32on Antiviral Research (ICAR) Baltimore MARYLAND PROGRAM and USA Hyatt Regency BALTIMORE ABSTRACTS May 12-15 2019 ND TABLE OF International Conference CONTENTS 32on Antiviral Research (ICAR) Daily Schedule . .3 Organization . 4 Contributors . 5 Keynotes & Networking . 6 Schedule at a Glance . 7 ISAR Awardees . 10 The 2019 Chu Family Foundation Scholarship Awardees . 15 Speaker Biographies . 17 Program Schedule . .25 Posters . 37 Abstracts . 53 Author Index . 130 PROGRAM and ABSTRACTS of the 32nd International Conference on Antiviral Research (ICAR) 2 ND DAILY International Conference SCHEDULE 32on Antiviral Research (ICAR) SUNDAY, MAY 12, 2019 › Women in Science Roundtable › Welcome and Keynote Lectures › Antonín Holý Memorial Award Lecture › Influenza Symposium › Opening Reception MONDAY, MAY 13, 2019 › Women in Science Award Lecture › Emerging Virus Symposium › Short Presentations 1 › Poster Session 1 › Retrovirus Symposium › ISAR Award of Excellence Presentation › PechaKucha Event with Introduction of First Time Attendees TUESDAY, MAY 14, 2019 › What’s New in Antiviral Research 1 › Short Presentations 2 & 3 › ISAR Award for Outstanding Contributions to the Society Presentation › Career Development Panel › William Prusoff Young Investigator Award Lecture › Medicinal Chemistry Symposium › Poster Session 2 › Networking Reception WEDNESDAY, MAY 15, 2019 › Gertrude Elion Memorial Award Lecture › What’s New in Antiviral Research 2 › Shotgun Oral
    [Show full text]
  • PDF Full-Text
    Review Article Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies Andrew Lee1,2*, Jeremy Rajanayagam1,3 and Mona Abdel-Hady1 1Birmingham Children’s Hospital, Liver Unit, Birmingham, United Kingdom; 2The University of Queensland, School of Medicine, Brisbane, Australia; 3University of Birmingham, School of Infection and Immunity, Birmingham, United Kingdom Abstract remains the most common method of infection in the developing world.1,2 The overall rate of spontaneous viral Viral hepatitis C is responsible for a large burden of disease clearance following childhood infection is low, with the worldwide. Treatment of hepatitis C infection is currently majority of children developing chronic hepatitis C (CHC) undergoing a revolution with the development of new direct (54–86%).2 The clinical course of CHC in children is usually acting antivirals that offer higher cure rates and fewer side silent, with mildly abnormal liver function tests (LFTs) and effects than other medications currently available. Treatment minimal inflammation and fibrosis on histology.2–4 options for children, although well-defined and evidence- Nevertheless, fibrosis tends to progress with time, culminat- based, are limited relative to adults as there are few trials ing in cirrhosis in 5–10% or hepatocellular carcinoma (HCC) regarding the use of these newly developed agents in in 2–5% in adulthood.2,3 Thus, continued efforts to effectively children. With so much optimism in the development of novel treat children and reduce the long-term health and social therapeutic options for hepatitis C, it is timely to review and consequences in pediatric CHC are justified. summarize the current standard of care treatment and indications for treatment of chronic hepatitis C in children.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Targeting Erbb3 Receptor in Cancer with Inhibitory Antibodies from Llama
    biomedicines Article Targeting ErbB3 Receptor in Cancer with Inhibitory Antibodies from Llama Igor E. Eliseev 1,2,3,* , Valeria M. Ukrainskaya 3, Anna N. Yudenko 4 , Anna D. Mikushina 1, Stanislav V. Shmakov 1, Anastasiya I. Afremova 5, Viktoria M. Ekimova 5, Anna A. Vronskaia 1, Nickolay A. Knyazev 6 and Olga V. Shamova 2 1 Laboratory of Renewable Energy Sources, Alferov University, St. Petersburg 194021, Russia; [email protected] (A.D.M.); [email protected] (S.V.S.); [email protected] (A.A.V.) 2 Center for Personalized Medicine, FSBSI Institute of Experimental Medicine, St. Petersburg 197376, Russia; [email protected] 3 Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia; [email protected] 4 Research Center for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology, Dolgoprudny 141700, Russia; [email protected] 5 CJSC Biocad, St. Petersburg 198515, Russia; [email protected] (A.I.A.); [email protected] (V.M.E.) 6 Saint-Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological), St. Petersburg 197758, Russia; [email protected] * Correspondence: [email protected] Abstract: The human ErbB3 receptor confers resistance to the pharmacological inhibition of EGFR and HER2 receptor tyrosine kinases in cancer, which makes it an important therapeutic target. Several anti- Citation: Eliseev, I.E.; Ukrainskaya, ErbB3 monoclonal antibodies that are currently being developed are all classical immunoglobulins. V.M.; Yudenko, A.N.; Mikushina, We took a different approach and discovered a group of novel heavy-chain antibodies targeting the A.D.; Shmakov, S.V.; Afremova, A.I.; extracellular domain of ErbB3 via a phage display of an antibody library from immunized llamas.
    [Show full text]
  • Ep 3178848 A1
    (19) TZZ¥__T (11) EP 3 178 848 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 14.06.2017 Bulletin 2017/24 C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) (21) Application number: 15198715.3 (22) Date of filing: 09.12.2015 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AL AT BE BG CH CY CZ DE DK EE ES FI FR GB yet been filed GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Cueni, Leah Noëmi et al Designated Extension States: F. Hoffmann-La Roche AG BA ME Patent Department Designated Validation States: Grenzacherstrasse 124 MA MD 4070 Basel (CH) (71) Applicant: F. Hoffmann-La Roche AG 4070 Basel (CH) (54) TYPE II ANTI-CD20 ANTIBODY FOR REDUCING FORMATION OF ANTI-DRUG ANTIBODIES (57) The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent comprising administration of a Type II anti-CD20 antibody, e.g. obinutuzumab, to the subject prior to administration of the therapeutic agent. EP 3 178 848 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 178 848 A1 Description Field of the Invention 5 [0001] The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent.
    [Show full text]
  • Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine Martin Pool1*, H
    Theranostics 2017, Vol. 7, Issue 7 2111 Ivyspring International Publisher Theranostics 2017; 7(7): 2111-2133. doi: 10.7150/thno.17934 Review Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine Martin Pool1*, H. Rudolf de Boer1*, Marjolijn N. Lub-de Hooge2, 3, Marcel A.T.M. van Vugt1#, Elisabeth G.E. de Vries1# 1. Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 2. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 3. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. * Co-first author # Co-senior author Corresponding authors: Elisabeth G.E. de Vries, MD, PhD, Marcel A.T.M. van Vugt, PhD, Department of Medical Oncology, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands +31 50 3612934 (EGEdV) / +31 50 3615002 (MATMvV) [email protected] / [email protected] © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2016.10.15; Accepted: 2017.03.02; Published: 2017.05.27 Abstract Cancer is a growing problem worldwide. The cause of death in cancer patients is often due to treatment-resistant metastatic disease. Many molecularly targeted anticancer drugs have been developed against ‘oncogenic driver’ pathways.
    [Show full text]
  • Phase Ib Study of Lumretuzumab Plus Cetuximab Or Erlotinib in Solid
    Published OnlineFirst June 9, 2017; DOI: 10.1158/1078-0432.CCR-17-0812 Cancer Therapy: Clinical Clinical Cancer Research Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity Didier Meulendijks1, Wolfgang Jacob2, Emile E. Voest1, Morten Mau-Sorensen3, Maria Martinez-Garcia4, Alvaro Taus4, Tania Fleitas5, Andres Cervantes5, Martijn P. Lolkema6,7, Marlies H.G. Langenberg6, Maja J. De Jonge7, Stefan Sleijfer7, Ji-Youn Han8, Antonio Calles9, Enriqueta Felip10, Sang-We Kim11, Jan H.M. Schellens1,12, Sabine Wilson2, Marlene Thomas2, Maurizio Ceppi2, Georgina Meneses-Lorente13, Ian James14, Suzana Vega-Harring2, Rajiv Dua15, Maitram Nguyen15, Lori Steiner15, Celine Adessi16, Francesca Michielin16, Birgit Bossenmaier2, Martin Weisser2, and Ulrik N. Lassen3 Abstract Purpose: This study investigated the safety, clinical activity, and Results: Altogether, 120 patients were treated. One dose-lim- target-associated biomarkers of lumretuzumab, a humanized, iting toxicity (DLT) in the cetuximab part and two DLTs in the glycoengineered, anti-HER3 monoclonal antibody (mAb), in erlotinib part were reported. The most frequent adverse events combination with the EGFR-blocking agents erlotinib or cetux- were gastrointestinal and skin toxicities, which were manageable. imab in patients with advanced HER3-positive carcinomas. The objective response rate (ORR) was 6.1% in the cetuximab part Experimental Design: The study included two parts: dose and 4.2% in the erlotinib part. In the sqNSCLC extension cohort escalation and dose extension phases with lumretuzumab in of the erlotinib part, higher tumor HRG and HER3 mRNA levels combination with either cetuximab or erlotinib, respectively.
    [Show full text]
  • Roche Group Development Pipeline
    Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group HY 2013 results Diagnostics Foreign exchange rate information 59 Changes to the development pipeline Q2 2013 update New to Phase I New to Phase II New to Phase III New to Registration 3 NMEs 3 NMEs 3 AIs 1 NME NDA submissions EU RG7410 in metabolic diseases RG7853 ALK inhibitor in NSCLC RG1273 Perjeta in HER2-positive and US RG7745 in infectious diseases RG7446 PD-L1 MAb in mNSCLC gastric cancer RG7159 obinutuzumab in CLL RG7842 in solid tumors RG7601 Bcl-2 inh in CLL RG435 Avastin in recurrent cervical 1 AI submission to FDA 3 AIs relapsed/refractory 17pdel cancer RG1273 Perjeta in neoadjuvant RG7446 PD-L1+Zelboraf in RG1569 Actemra in giant cell HER2-positive breast cancer metastatic melanoma arteritis RG7446 PD-L1 + Avastin in solid tumors RG7446 PD-L1 in solid tumors Removed from Removed from Phase I Removed from Phase II Removed from Phase III Registration 1 NME due to selection of 1 NME 2 NMEs 1 NME EU approval alternative molecule RG7160 imgatuzumab (GA201, RG1439 aleglitazar CV risk RG3616 Erivedge in advanced RG7112 MDM2 ant. in solid and EGFR MAb) in solid tumors reduction post ACS in type 2 basal cell carcinoma hematological tumors 2 AIs diabetes; complete programme 1 AI EU+US approval RG3638 onartuzumab in triple-neg terminated RG1569 RoActemra/Actemra in mBC 1st/2nd line SST arbaclofen in fragile X syndrome polyarticular
    [Show full text]